| __timestamp | Ascendis Pharma A/S | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 2983000000 |
| Thursday, January 1, 2015 | 9415000 | 3426000000 |
| Friday, January 1, 2016 | 11504000 | 3398000000 |
| Sunday, January 1, 2017 | 13482000 | 3878000000 |
| Monday, January 1, 2018 | 25057000 | 4056000000 |
| Tuesday, January 1, 2019 | 48473000 | 4381000000 |
| Wednesday, January 1, 2020 | 76669000 | 5151000000 |
| Friday, January 1, 2021 | 160180000 | 5246000000 |
| Saturday, January 1, 2022 | 221227000 | 5673000000 |
| Sunday, January 1, 2023 | 264410000 | 6090000000 |
| Monday, January 1, 2024 | 284545000 | 6091000000 |
Unleashing the power of data
In the dynamic world of biopharmaceuticals, understanding operational efficiency is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Gilead Sciences, Inc. and Ascendis Pharma A/S from 2014 to 2023. Gilead, a stalwart in the industry, consistently outpaces Ascendis in SG&A spending, reflecting its expansive operations. In 2023, Gilead's SG&A expenses reached approximately $6.09 billion, a 104% increase from 2014. Meanwhile, Ascendis, a rising star, saw its SG&A expenses grow by an astounding 4,110% over the same period, reaching $264 million in 2023. This stark contrast highlights Gilead's established market presence and Ascendis's rapid growth trajectory. As Ascendis scales, its SG&A efficiency will be pivotal in sustaining its competitive edge. This comparison underscores the diverse strategies employed by biopharma companies to manage operational costs while driving innovation.
Selling, General, and Administrative Costs: Johnson & Johnson vs Gilead Sciences, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Takeda Pharmaceutical Company Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and ImmunityBio, Inc.
Gilead Sciences, Inc. vs Novavax, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation